Gotu Kola for Venous Insufficiency and Circulation

Heavy, aching legs that swell by evening. Ankles that leave a sock mark. A dull throb after a day standing at work, relieved by putting your feet up. That cluster is chronic venous insufficiency, and it is the second of gotu kola’s two evidence-backed uses — the one where the standardised extract was studied hardest, by a small number of European research groups, mostly between 1987 and 2001.

That date range is the whole story of this article. The evidence is real, it is measured with objective instruments rather than opinion, and it is old, small, concentrated in a handful of laboratories, and published substantially in a single sponsored journal supplement. All of that is knowable from the papers themselves, and all of it is left out of supplement copy. Here it is in full.

Table of Contents

  1. What Chronic Venous Insufficiency Actually Is
  2. Why a Connective-Tissue Herb Was Tried Here
  3. TTFCA and the Doses Actually Studied
  4. The 1987 Multicentre Trial
  5. The Italian Microcirculation Programme
  6. What the 2013 Systematic Review Concluded
  7. Flight Oedema and Diabetic Microangiopathy
  8. The Honest Limitations
  9. Where It Fits Beside Compression
  10. Practical Use
  11. Cautions and Red Flags
  12. Key Research Papers
  13. Connections
  14. Featured Videos

What Chronic Venous Insufficiency Actually Is

Leg veins have to move blood uphill. They manage it because the calf muscles squeeze them with every step and one-way valves stop the blood falling back between squeezes. When those valves leak — from age, pregnancy, genetics, prolonged standing, obesity or a previous clot — blood pools in the lower leg and the pressure inside the veins stays high even when you are walking. That sustained pressure is called venous hypertension, and it is what does the damage.

High pressure pushes fluid out of the capillaries into the tissue faster than the lymphatics can clear it. That is the swelling. Over years the leaked fluid carries proteins and red cells with it, and the skin around the ankle becomes discoloured, thickened and fragile — and eventually, in some people, ulcerates.

The clinical stages run roughly: telangiectasia and spider veins, then varicose veins, then oedema, then skin changes (pigmentation, eczema, lipodermatosclerosis), then healed ulcer, then active ulcer. Gotu kola has been studied at the early and middle end of that ladder — symptoms, oedema and capillary leak. It has not been shown in a randomised trial to heal ulcers or to prevent progression to them. One 2025 registry from the same Chieti research group, which was not randomised or blinded, reported faster ulcer closure when an oral standardised Centella extract was added to standard ulcer care (details under The Honest Limitations).

Why a Connective-Tissue Herb Was Tried Here

The rationale is the same chemistry that underlies the wound-healing use, pointed at a different tissue. A vein wall is largely connective tissue — collagen, elastin and the cells that maintain them. A capillary wall is a single layer of endothelium sitting on a basement membrane. If a compound modulates fibroblast behaviour, collagen synthesis and endothelial integrity, then a leaky, distensible, chronically stretched vein is a reasonable place to test it.

The specific claims made for the triterpenic fraction in this setting are that it improves the tone and reduces the distensibility of the vein wall, and that it reduces the abnormal permeability of the capillaries in the affected skin. Both were tested with instruments rather than questionnaires, which is the strongest single feature of this literature.

TTFCA and the Doses Actually Studied

The venous trials used the standardised fraction, referred to as TTFCA (total triterpenic fraction of Centella asiatica) or TECA (titrated extract). It is not dried leaf and not a tea.

StudyRegimenDaily totalDuration
Pointel 1987Two arms versus placebo60 mg and 120 mg2 months
Belcaro 199060 mg three times daily180 mg2 weeks
Cesarone 199430 mg or 60 mg twice daily versus placebo60 mg and 120 mg60 days
De Sanctis 200130 mg or 60 mg three times daily90 mg and 180 mg4 weeks
Incandela 2001 (venous)Two dose levels versus placebo60 mg and 120 mgShort term
Cesarone 2001 (flights)60 mg three times daily180 mg2 days before, day of, 1 day after flight
Incandela 2001 (diabetic)60 mg twice daily120 mg12 months
Cesarone 2001 (diabetic)60 mg twice daily120 mg6 months

So the studied range is roughly 60 to 180 mg of the triterpenic fraction per day, in two or three divided doses, for periods from a few days to a year. Where dose-ranging was done, higher doses generally did more: De Sanctis and colleagues concluded that 180 mg/day beat 90 mg/day, and Incandela and colleagues distinguished 120 mg/day from 60 mg/day on objective measures.

The 1987 Multicentre Trial

The most conventionally designed study in the set is also the oldest. Pointel and colleagues, publishing in Angiology in 1987, enrolled 94 patients with venous insufficiency of the lower limbs into a multicentre, double-blind, placebo-controlled trial. After randomisation they received TECA 120 mg/day, TECA 60 mg/day, or placebo for two months.

Findings:

That last detail is worth pausing on. The instrument result was not merely “treated group better” but “treated group improved while untreated group deteriorated”, over a period long enough for natural progression to show. It is the single most persuasive piece of data in the gotu kola venous literature. It is also thirty-nine years old, with roughly thirty patients per arm, reported in an abstract that does not describe the randomisation or blinding procedure in any detail.

The Italian Microcirculation Programme

Nearly everything else comes from one interconnected research effort centred on Gianni Belcaro, Maria Rosaria Cesarone, Maria Teresa De Sanctis and Luciano Incandela, working between the G. D’Annunzio University in Chieti, Italy and the Irvine Vascular Laboratory at St Mary’s Hospital, London. Their contribution was methodological: instead of asking patients whether their legs felt better, they built a battery of microcirculatory measurements.

The instruments, in plain terms

What they reported

Belcaro 1990 used the VSC device with laser Doppler in 10 normal subjects, 22 patients with moderate superficial venous hypertension and 12 with post-phlebitic limbs and severe venous hypertension. Each was observed for two weeks untreated, then treated for two weeks with TTFCA 60 mg three times daily. Wheal disappearance time was longer in the patients than the controls at baseline, unchanged over the untreated fortnight, and significantly shorter after treatment — alongside improvement in microcirculatory measures and symptoms. The untreated run-in period is a genuine strength: it shows the change tracked the drug rather than the passage of time.

De Sanctis 2001 was a dose-ranging, placebo-controlled study: 20 patients on 180 mg/day, 20 on 90 mg/day, 12 on placebo, and 10 healthy subjects also given 180 mg/day as a reference. After four weeks, capillary filtration rate, ankle circumference and ankle-swelling time all fell significantly in the treated patients, more so at the higher dose. Nothing changed on placebo — and, notably, nothing changed in the healthy subjects taking the drug, which is what you would expect if the effect depends on abnormal capillary leak being present in the first place.

Incandela 2001, a single-blind, placebo-controlled, randomised study, combined laser Doppler with transcutaneous gas measurements in patients with venous hypertensive microangiopathy, and found that the whole battery separated 120 mg/day from 60 mg/day from placebo, with symptom scores moving in parallel with the instrument readings.

Cesarone 1994, published in Italian in Minerva Cardioangiologica, was an earlier double-blind study of microcirculatory activity in venous insufficiency from the same group. It enrolled 87 patients with venous hypertensive microangiopathy, who took 30 mg twice daily, 60 mg twice daily, or placebo for 60 days. Compared with the values at the start, the abnormally raised resting skin flux improved, transcutaneous PCO2 fell and PO2 rose; the effects appeared dose-related, and no unwanted effects were observed.

What the 2013 Systematic Review Concluded

Chong and Aziz at the University of Malaya searched thirteen electronic databases including the Cochrane Central Register for randomised trials of Centella asiatica in chronic venous insufficiency. Eight studies met inclusion criteria, and two authors independently extracted data.

Their findings:

That is a fair verdict and worth reading twice. The direction of effect is consistent. The quality of the underlying reports is not good enough to be confident about the size of it.

A 2026 network meta-analysis

A 2026 network meta-analysis compared drug treatments for chronic venous disease across 51 randomised trials with 6,800 patients. Centella asiatica significantly reduced leg heaviness compared with control (risk ratio 0.30, 95% confidence interval 0.11 to 0.81), as did calcium dobesilate. The treatments that significantly improved ulcer healing in that analysis were pentoxifylline, micronised purified flavonoid fraction and sulodexide.

Flight Oedema and Diabetic Microangiopathy

The same group extended TTFCA into two adjacent problems.

Flight-related leg swelling. Cesarone and colleagues studied passengers aged 30–50 with mild-to-moderate superficial venous disease and varicose veins, travelling in economy class on flights longer than three hours. The treated group took TTFCA 60 mg three times daily for two days before the flight, on the day itself, and for one day after. In untreated controls, carbon dioxide, rate of ankle swelling and oedema score rose progressively with flight time while skin flux and the venoarteriolar response fell. In the TTFCA group the changes in all measures were milder, though that difference was not statistically significant (p > 0.05), and ankle swelling and oedema were significantly lower (p < 0.025). Note that the control group received no treatment at all — there was no placebo, so expectation effects are uncontrolled.

Diabetic microangiopathy. Incandela and colleagues ran a twelve-month placebo-controlled study of TTFCA 60 mg twice daily in patients with diabetic microangiopathy, with and without neuropathy, alongside healthy controls. Resting flux and rate of ankle swelling fell in the treated groups, with a corresponding decrease in oedema; untreated patients deteriorated progressively over the year while healthy subjects did not change. A companion paper from the same programme (Cesarone 2001) studied 50 people with diabetic microangiopathy: 30 took TTFCA 60 mg twice daily for six months, 10 took placebo and 10 received no treatment. After six months neither control group had changed significantly, while in the treated group resting skin flux fell, the venoarteriolar response improved, PO2 rose, PCO2 fell and the abnormally raised capillary leak (rate of ankle swelling) decreased. Twelve months is a long study for a botanical, and progressive deterioration in the placebo arm is a meaningful comparator.

The same laboratory also published a study on the echogenicity of carotid plaques after TTFCA in the same 2001 supplement, which gives a sense of how broadly the group was testing this single compound.

The Honest Limitations

Five, in order of importance.

  1. One research programme dominates the evidence. A large share of the trials share overlapping authors, a shared laboratory, and shared methods. Independent replication by unconnected groups is what converts a promising finding into an established one, and it has largely not happened here. The newest addition comes from the same Chieti laboratory: a 2025 registry of 160 people with venous ulcers, 80 of whom took an oral standardised Centella extract (675 mg a day for three months) on top of standard ulcer care while 80 received standard care alone. Average ulcer area fell from 2.34 to 0.33 cm² with the extract and from 2.4 to 1.61 cm² without it, and 96.2% versus 83.7% of ulcers closed completely. The study was not randomised or blinded, so it extends the single-group problem rather than resolving it.
  2. Much of it appeared in a single journal supplement. Angiology volume 52, supplement 2, October 2001, carries a run of TTFCA papers back to back. Supplement issues are frequently sponsored and are not always subject to the same peer review as the parent journal. This does not make the data false. It does mean they carry less weight than the same results in a regular issue.
  3. The endpoints are mostly surrogates. Capillary filtration rate and transcutaneous gas tensions are legitimate physiological measures, and better than a satisfaction score — but no trial shows that treating them with gotu kola prevents a venous ulcer, prevents progression, or reduces the need for a procedure. Those are the outcomes patients actually care about.
  4. The studies are small and short. Arms of 10 to 30 patients. Durations of two to eight weeks, with a six-month and a twelve-month exception. Nothing here is a modern multicentre trial.
  5. Reporting quality is poor by current standards. The systematic reviewers said so directly, and three of eight trials could not even be pooled for want of numbers.

Where It Fits Beside Compression

Compression is the foundation of venous care, and nothing displaces it. Graduated compression stockings work by external mechanics: they oppose the pressure driving fluid out of the capillaries. Calf-muscle activity, leg elevation, and weight management do the same job from other directions. For varicose veins with symptoms, endovenous ablation and related procedures treat the underlying reflux.

Venoactive drugs — the class gotu kola belongs to — are adjuncts to that, not substitutes. The class also includes micronised purified flavonoid fraction (diosmin and hesperidin), horse chestnut seed extract, ruscus preparations and hydroxyethylrutosides. Some of those have a larger trial base than gotu kola does.

A 2020 Cochrane review looked at these drugs as a class (called phlebotonics). It included 69 randomised trials, 56 of which gave usable data on 7,690 people; two of those tested Centella asiatica. Compared with placebo, it found that the class probably reduces lower-leg swelling slightly (risk ratio 0.70, moderate certainty) and probably makes little or no difference to quality of life (moderate certainty), and that the drugs may have little or no effect on ulcer healing (risk ratio 0.94, low certainty). They probably cause slightly more side effects than placebo (risk ratio 1.14, moderate certainty), most often stomach and bowel upset. The trials gave only short-term safety data.

MeasureRealistic expectation from TTFCA
Leg heaviness and achingModest improvement, seen in trials
Ankle and leg swellingMeasurable reduction at 90–180 mg/day
Capillary leak measuresConsistently improved in instrumented studies
Visible varicose veinsNo evidence of change
Preventing ulcers or progressionNot demonstrated
Replacing compressionNo — nothing supports this

Practical Use

Cautions and Red Flags

Key Research Papers

  1. Chong NJ, Aziz Z. A systematic review of the efficacy of Centella asiatica for improvement of the signs and symptoms of chronic venous insufficiency. Evidence-Based Complementary and Alternative Medicine. 2013;2013:627182 — PubMed PMID: 23533507 — Eight trials; benefit on microcirculatory parameters; unclear risk of bias throughout.
  2. Pointel JP, Boccalon H, Cloarec M, Ledevehat C, Joubert M. Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs. Angiology. 1987;38(1 Pt 1):46–50 — PubMed PMID: 3544968 — 94 patients, multicentre, double-blind, 60 and 120 mg/day versus placebo.
  3. Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. Angiology. 1990;41(7):533–540 — PubMed PMID: 2389834 — Vacuum suction chamber study with a two-week untreated run-in.
  4. De Sanctis MT, Belcaro G, Incandela L, Cesarone MR, Griffin M, Ippolito E, et al. Treatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a clinical, prospective, placebo-controlled, randomized, dose-ranging trial. Angiology. 2001;52(Suppl 2):S55–S59 — PubMed PMID: 11666125 — 180 mg/day outperformed 90 mg/day.
  5. Incandela L, Belcaro G, De Sanctis MT, Cesarone MR, Griffin M, Ippolito E, et al. Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. Angiology. 2001;52(Suppl 2):S61–S67. — PubMed PMID: 11666126
  6. Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C, et al. [The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study.] Minerva Cardioangiologica. 1994;42(6):299–304 — PubMed PMID: 7936334 — In Italian.
  7. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Geroulakos G, Griffin M, et al. Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001;52(Suppl 2):S33–S37 — PubMed PMID: 11666121 — No placebo arm — controls were untreated.
  8. Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Nargi E, Patricelli P, et al. Treatment of diabetic microangiopathy and edema with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled randomized study. Angiology. 2001;52(Suppl 2):S27–S31 — PubMed PMID: 11666119 — Twelve months, 120 mg/day.
  9. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Bavera P, Bucci M, et al. Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella asiatica: a clinical prospective randomized trial with a microcirculatory model. Angiology. 2001;52(Suppl 2):S49–S54. — PubMed PMID: 11666124
  10. Cesarone MR, Belcaro G, Nicolaides AN, Geroulakos G, Bucci M, Dugall M, et al. Increase in echogenicity of echolucent carotid plaques after treatment with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled, randomized trial. Angiology. 2001;52(Suppl 2):S19–S25 — PubMed PMID: 11666118 — Included to show the breadth of the same programme, not as evidence of cardiovascular benefit.
  11. Grimaldi R, De Ponti F, D’Angelo L, Caravaggi M, Guidi G, Lecchini S, et al. Pharmacokinetics of the total triterpenic fraction of Centella asiatica after single and multiple administrations to healthy volunteers. A new assay for asiatic acid. Journal of Ethnopharmacology. 1990;28(2):235–241 — PubMed PMID: 2329813 — Confirms oral absorption.
  12. Nguyen AN, Ta KT, Chuang KJ. Pharmacological interventions to treat chronic venous disease: a network meta-analysis. Phlebology. 2026 (online ahead of print). — PubMed PMID: 42529868 — 51 trials, 6,800 patients; Centella reduced leg heaviness.
  13. Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews. 2020;11(11):CD003229. — PubMed PMID: 33141449 — The drug class as a whole; two Centella trials included.
  14. Belcaro G, Dugall M, Cesarone MR, Ledda A, Ippolito E, Corsi M, Hosoi M, Scipione V, Scipione C, Cotellese R, Feragalli B. Improvement in venous ulcer closure and healing with Centellicum®. Minerva Surgery. 2025;80(4):308–313. — PubMed PMID: 40719428 — Non-randomised registry, 160 people with venous ulcers.
  15. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of Centella asiatica. Revista Española de Enfermedades Digestivas. 2005;97(2):115–124. — PubMed PMID: 15801887 — Three cases of liver injury.
  16. Fogacci F, Di Micoli V, Avagimyan AA, ALGhasab NS, Perone F, Cicero AFG. Lifestyle strategies and nutraceuticals in chronic venous disease: an evidence-weighted synthesis and clinical positioning. Clinical Nutrition. 2026;66:106801. — PubMed PMID: 42828782
  17. Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine. 2000;7(5):427–448 — PubMed PMID: 11081995 — Reviews the venous literature as it stood in 2000.

PubMed Topic Searches

  1. PubMed: Centella asiatica and chronic venous insufficiency
  2. PubMed: TTFCA and capillary filtration
  3. PubMed: Venoactive drugs in chronic venous disease — guidelines
  4. PubMed: Horse chestnut seed extract — the better-studied comparator
  5. PubMed: Compression therapy for venous leg ulcers
  6. PubMed: Centella asiatica and diabetic microangiopathy

Connections

Back to Table of Contents